Martin Holst Lange

I would answer, it's been a few years since we designed the redefined program, the program to show the weight loss potential of Calc with Sema.

We already last year learned that to really see the true weight loss potential of CAGROSEMA, it is a very powerful combination of two molecules.

We need to have what we call a bespoke titration algorithms to really allow patients to titrate the very powerful treatment in the way that they prefer.

We could see from the first study that that could be further optimized.

In this setting, we could not manage to implement those learnings in what we call redefined form, which is the study that we discussed today.

So the jury is still out of what can kagrisema actually achieve.

In the study that read out today, we saw 23% weight loss with kagrisema.

That is actually very substantial, and it is among the best weight losses that we've seen, also amongst drugs in the market.

Yeah, exactly.

So first of all, the 23% weight loss that we saw with the Cagrosema is in line with what we've previously seen.

The 25%, which we saw with the comparator drug, is actually the best data that has been seen so far in similar trials, which is a little bit surprising, but it stands alone in terms of that 25%.

But we've also taken a lot of learnings in terms of how we can improve the titration for chagrissima.

We've implemented those learnings in a study that's currently ongoing.

That study is called Redefine11.

And we've guided for the last year that only when we see those data do we know the full weight loss potential of chagrissima.

Furthermore, we are initiating, during this year, phase three studies to investigate even higher doses of CagriSemma.

And then, obviously, we have our very competitive pipeline, starting with Senna-Gemta that starts phase three this year, but also our two triagonists that is currently in phases one and two.

So I think from a short, but also a longer-term perspective, we have a very competitive portfolio and pipeline.

The way we think about this is that obesity is a very complex disease and obviously we want to have drugs that provide the biggest weight loss, but we also want to have drugs that gives as few side effects as possible.

We also want to have drugs that provide comorbidities and to an extent in our current portfolio we have all of that.